According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “
Separately, Cowen and Company reaffirmed a buy rating on shares of Cascadian Therapeutics in a research note on Monday, October 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $3.20.
Cascadian Therapeutics (NASDAQ:CASC) traded down 1.53% during mid-day trading on Tuesday, reaching $1.29. 38,060 shares of the company were exchanged. The stock’s 50-day moving average price is $1.36 and its 200-day moving average price is $1.18. The stock’s market capitalization is $174.55 million. Cascadian Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.75.
Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.14. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. On average, equities research analysts anticipate that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.
In other Cascadian Therapeutics news, insider Scott Dunseth Myers acquired 45,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The stock was purchased at an average cost of $1.15 per share, with a total value of $51,750.00. Following the transaction, the insider now owns 107,500 shares of the company’s stock, valued at $123,625. The transaction was disclosed in a filing with the SEC, which is available at this link. 19.40% of the stock is owned by company insiders.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.